Saudi AR, Importer or Distributor

The local-role design determines who controls decisions, data and risk

Manufacturers often use authorized representative, importer and distributor as if they were interchangeable names for one Saudi partner. They are distinct regulatory and operating functions. The AR represents an overseas manufacturer in relation to the Medical Devices Law and Regulation. The importer brings devices into the Kingdom. The distributor supplies another distributor or the end user. Each role requires the relevant licensed scope and capability.

One company may combine several roles when properly licensed and equipped, while another manufacturer may keep regulatory representation separate from sales. The choice depends on portfolio breadth, channel concentration, control of data, resilience when a distributor changes, and the parties’ post-market capacity.

The AR anchors regulatory continuity

MDS-REQ 9 defines the AR as a Saudi-based legal person with written authorization from an overseas manufacturer to represent it in implementing the Medical Devices Law and Regulation. MDS-REQ 1 places the overseas manufacturer and its licensed AR within the marketing-authorization pathway.

The work is broader than submitting an application. The AR needs access to product changes, complaints and regulatory records, and must be able to communicate with the SFDA. An arrangement tied entirely to sales, without transition and file-handover provisions, can make a later channel change unnecessarily disruptive.

Test whether the AR can absorb and preserve regulatory knowledge, not merely receive documents. The operating model should identify who funds and leads renewals, change assessments and authority responses, how decisions are recorded, and what information must be transferred if the mandate changes. Regulatory continuity should not depend on the health of a commercial dispute.

The importer owns the shipment interface

An importer is an establishment in the supply chain that imports a medical device into Saudi Arabia. MDS-REQ 5 connects commercial importation to the importer license, valid authorization and shipment documentation and clearance processes.

Selection should go beyond checking that a license exists. Examine category experience, document review, discrepancy management, transport and storage controls, lot or serial traceability, and coordination with logistics providers. An importer that treats the shipment as freight alone can disconnect the goods from their regulated identity.

To turn this analysis into a product-specific plan, review Authorized Representative and Local Role Support and the related regulatory insight.

Use a controlled shipment scenario during due diligence. Ask the candidate to identify a model mismatch, explain the stop-and-escalate route, and show how a lot or serial number moves from receipt to storage and customer delivery. Redacted deviation logs and escalation records reveal more about capability than a generic statement of experience.

The distributor controls the customer interface

A distributor provides a medical device to another distributor or to the end user. Commercial activities may include account coverage, inventory, promotion, training and collection, depending on the contract and licensed scope.

Assess capability in the actual category. Customer access, pricing discipline, demand data, inventory management, technical personnel and complaint response matter more than a large generic sales force. The agreement should also address ownership and transfer of customer and distribution records when the relationship ends.

Review coverage at account and product level. A partner can be strong in capital equipment but weak in consumables, or commercially connected but unable to service installed devices. A practical ninety-day plan should name accountable people, priority accounts, inventory assumptions and conversion measures, then distinguish demonstrated capability from forecast ambition.

Define conflict-of-interest and competing-brand rules as well. A competing line is not automatically disqualifying, but it requires disclosure, resourcing, data protection and measurable commitments. Monitor forecast accuracy, stock availability, complaint closure, traceability records and training quality alongside revenue. Exit provisions should cover files, customer and distribution data, open complaints, inventory and service continuity; planning the transition protects patients and the market rather than signalling distrust.

Post-market duties connect every party

MDS-REQ 11 requires traceability and incident or complaint procedures across manufacturers, ARs, importers and distributors, and addresses field actions and after-sales activities. QMS inspection requirements also apply to these entities according to activity.

Breakdowns usually occur at the interfaces. A distributor receives a complaint but the AR never sees it; the importer holds lot data but the manufacturer lacks customer distribution records; or the manufacturer initiates an FSCA without a Saudi execution plan. Written interfaces and a periodic simulation are more useful than parallel procedures that never meet.

Combine roles or separate them

Combining AR, import and distribution can reduce handoffs and speed decisions. It also increases dependence on one partner and may make change difficult if that partner controls market data and customer relationships. Separation can increase resilience and manufacturer visibility, but it requires stronger governance and coordination.

A broad portfolio using several channels may benefit from an independent AR with multiple importers or distributors. A focused portfolio requiring specialized service and inventory may favor an integrated partner. This is a commercial design choice that must remain compatible with licensing, the product and the agreement.

Local-role decision matrix

Compare candidates across seven dimensions: licensed scope, regulatory independence, buyer access, import and inventory capacity, training and maintenance, traceability and FSCA execution, and data ownership and exit readiness.

For each dimension, record evidence, the accountable party, dependencies and failure impact. Then prepare a RACI across MDMA and changes, shipment, storage, sales, training, complaints, reporting, recall and maintenance. Any activity without one accountable owner should be resolved before appointment.

Write the agreement around operations

The agreement should match the regulated operating model. Define products, roles and licenses; file access; internal notification routes; customer-data ownership; approval of promotional materials; service levels; audit rights; and transition obligations. No party should promise an SFDA approval or tender outcome it cannot control.

Basier can design the role model and convert it into a regulatory and operational due-diligence checklist before contracting. The analysis starts with the portfolio and intended buyer channel, not a shortlist of partner names.

Verify each establishment’s current license type, scope and status in official records before appointment. Contract allocation does not automatically transfer statutory responsibility and may require separate legal review.

References: [1] [2] [3] [4] [5] [6]